Skip to main content

Table 1 Characterization of Patient and Prior Treatments

From: Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis

Patient Age (Years) Sex HPV type Age at diagnosis (Years) Number of RRP surgeries lifetime Prior local treatments Prior systemic treatments Pulmonary RRP lesions
1 32 F 11 19 > 40 Cidofovir I-3-C No
2 36 M 6 28 35 Cidovofir, bevacizumab I-3-C No
3 50 F 11 5 > 250 Mitomycin Diindolylmethane Yes
4 63 M 11 19 > 50 Cidofovir, Cryotherapy None No
5 27 F 6 6 > 50 None None No
6 53 F 11 38 > 20 Cidofovir None Yes
7 55 M 6 53 11 Cidovofir, bevacizumab None No
8 55 F 6 51 16 None None No
9 56 M 11 54 > 20 Cidofovir None No
10 21 M 6 1 > 100 Cidovofir, bevacizumab Interferon, Methotrexate Yes
11 67 M 6 28 > 40 bevacizumab, PDT I-3-C Yes
12 26 M 11 2 > 100 Cidofovir, bevacizumab Interferon, I-3-C No
  1. Abbreviations: HPV human papillomavirus, RRP recurrent respiratory papillomatosis, PDT photodynamic therapy, I-3-C indole-3-carbinol